#TAGR 3.1.1 UPDATE#
#TAGR 3.1.1 TRIAL#
#TAGR 3.1.1 LICENSE#

20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NovemDate of report (Date of earliest event reported) GENPREX, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DecemDate of report (Date of earliest event reported) GENPREX, INC. Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits Regulation FD Disclosure, Financial Statements and Exhibits, Other Events (Eĭeparture of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FebruDate of report (Date of earliest event reported) GENPREX, INC. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 MaDate of report (Date of earliest event reported) GENPREX, INC. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) GENPREX, INC. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 JDate of report (Date of earliest event reported) GENPREX, INC.

#TAGR 3.1.1 TRIAL#

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review as Chief Manufacturing and Technology Officer Seasoned innovative drug development executives bolster lead as Chief Medical Officer and Hemant Kumar, Ph.D. Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S.

FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination with Keytruda® for the Treatment of Non-Small Cell Lung Cancer Second FDA Fast Track Designation Further Validates the Potential of REQORSA Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer Pipeline Expansion Enables Company to Target Entire Lung Cancer Market with REQORSA™ Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Company has FDA Fast Track Designation for combination of REQORSA and Tagriss Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination with Keytruda® to Treat Non-Small Cell Lung Cancer Company Has FDA Fast Track Designation for Combination of REQORSA

#TAGR 3.1.1 UPDATE#

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Gen ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING WITH A SINGLE, HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR

#TAGR 3.1.1 LICENSE#

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh Latest license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company’s diabetes gene therapy program Innovat Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Calidad + Valor + Sentimiento de los Fondos.

Tagr 3.1.1